In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
The study, a multicenter, open-label trial conducted in Korean patients with childhood-onset NS, involved patients aged under 24 years who were either drug-dependent for more than 2 years or who were intolerant to standard treatment.
The study’s design involved a randomized controlled trial (RCT) for drug-dependent patients and a single-arm study for patients whose disease was resistant to conventional treatment. In the RCT, patients were randomly assigned to receive either rituximab (n = 40) or standard treatment (n = 21), and in the single-arm study, all patients (n = 23) received rituximab in addition to their pre-enrollment treatment.
The primary end points of the study were the rate of retaining remission at 6 months in the RCT and the rate of remission within 6 months of starting rituximab in the single-arm study.
In the RCT, at 6 months, 74.3% of rituximab-treated patients were at remission, while 68.7% of standard therapy patients in the control group were in relapse (P = .003). The median duration of remission in the rituximab group was 9 months versus 2.9 months in the standard therapy group.
In the single-arm study, within 6 months of starting rituximab, 9 patients achieved either partial (n = 2) or complete (n = 7) remission.
In all patients treated with rituximab, CD19-positive B cells were depleted within 2 weeks of rituximab treatment. However, relapse after rituximab was not always linked with B-cell recovery; 4 patients had depleted B cells at the time of NS relapse.
In total, 50.8% of patients had infusion reactions to rituximab, and 5 of these patients discontinued infusion (all 5 patients were able to tolerate subsequent rituximab administrations, however). A total of 21 patients reported infections, and 45 experienced any AE. One patient died during the study, but the death was not attributable to rituximab therapy, the investigators concluded.
“Our study laid one more piece of evidence that [rituximab] can be safe and effective in patients with childhood-onset, medication-dependent NS,” wrote the authors, adding that controlled studies are warranted to determine the optimal dosing and interval for rituximab administration in patients with hard-to-treat NS.
Reference
Anh YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore). 2018;97:e13158. doi: 10.1097/MD.0000000000013157.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.